Pre-Made Baminercept Biosimilar, Fusion Protein targeting LTA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LT/TNFB/TNFSF1/TNLG1E for drug discovery and mechanism of action (MOA) research

Pre-Made Baminercept Biosimilar, Fusion Protein targeting LTA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LT/TNFB/TNFSF1/TNLG1E is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Baminercept is a lymphotoxin ¦Â receptor IgG fusion protein (LT¦ÂR-Ig), for the treatment of primary Sj?gren’s syndrome (SS). Primary Sj?gren¡¯s syndrome (pSjS) is characterized by chronic inflammation of the lacrimal and salivary glands, as well as frequent extra glandular involvement and increased risk of B cell lymphoma. Several lines of evidence implicate the lymphotoxin (LT) pathway in the pathogenesis of this disease. Baminercept inhibits the LT pathway, which is important in lymphoid tissue organization and chronic inflammation.